Evidence map›Paper›PMID 24736702›Full record

ReviewAdvances in dental research2014

Recent advances in host defense mechanisms/therapies against oral infectious diseases and consequences for systemic disease.

S L Gaffen, M C Herzberg, M A Taubman, T E Van Dyke

Open access · greenAbstract readReview
In one paragraph

Review in Advances in dental research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. International journal of molecular sciences · 2020
    Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Journal of oral microbiology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

S L GaffenDepartment of Medicine, University of Pittsburgh, Division of Rheumatology & Clinical Immunology, S702 BST, 3500 Terrace Street, Pittsburgh, PA 15261, USA.
M C Herzberg
M A Taubman
T E Van Dyke
Harvard University · USUniversity of Minnesota · USUniversity of Pittsburgh · US

Funding

REGULATORY CELLS IN EXPERIMENTAL PERIODONTAL DISEASER01DE003420 · NIDCR · FORSYTH INSTITUTE · PI KAWAI, TOSHIHISA · 1985 to 2012
$4.3M
Neutrophils and Periodontitis in DiabetesR01DE015566 · NIDCR · BOSTON UNIVERSITY MEDICAL CAMPUS · PI VAN DYKE, THOMAS ELLIOTT · 2005 to 2014
$4.2M
Novel Mechanisms in Resolution to Harness Inflammation for ReconstructionR01DE019938 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · PI IRIMIA, DANIEL, SERHAN, CHARLES NICHOLAS · 2009 to 2012
$2.7M
IL-17 Receptor Signaling in the Oral MucosaR01DE022550 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GAFFEN, SARAH L · 2012 to 2016
$2.1M
T-Regulatory Cells in PeriodontitisR01DE018499 · NIDCR · ADA FORSYTH INSTITUTE, INC. · PI KAWAI, TOSHIHISA · 2008 to 2011
$1.9M
IL-23/STAT3-Driven Oral Immune Responses to Candida albicansR01DE023815 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GAFFEN, SARAH L · 2014 to 2018
$1.9M
Negative Control of IL-17R Signaling: Implications for Fungal ImmunityR01AI107825 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GAFFEN, SARAH L · 2014 to 2018
$1.9M
Augmenting Innate Immunity to Protect the Oral MucosaR01DE021206 · NIDCR · UNIVERSITY OF MINNESOTA · PI HERZBERG, MARK C · 2010 to 2013
$1.2M
REGULATORY CELLS IN EXPERIMENTAL PERIODONTAL DISEASER37DE003420 · NIDCR · FORSYTH INSTITUTE · PI TAUBMAN, MARTIN A · 1990 to 1999
–
NIAID NIH HHS R01 AI107825NIDCR NIH HHS DE018499NIDCR NIH HHS DE021831NIDCR NIH HHS DE 03420NIDCR NIH HHS DE19938NIDCR NIH HHS R01 DE003420NIDCR NIH HHS R01 DE015566NIDCR NIH HHS R01 DE018499NIDCR NIH HHS R01 DE019938NIDCR NIH HHS R01 DE021206NIDCR NIH HHS R01DE021206NIDCR NIH HHS R01 DE022550NIDCR NIH HHS R01 DE023815NIDCR NIH HHS R37 DE003420PHS HHS 15566
6 · The paper itself

Abstract

The innate and adaptive immune systems are both crucial to oral disease mechanisms and their impact on systemic health status. Greater understanding of these interrelationships will yield opportunities to identify new therapeutic targets to modulate disease processes and/or increase host resistance to infectious or inflammatory insult. The topics addressed reflect the latest advances in our knowledge of the role of innate and adaptive immune systems and inflammatory mechanisms in infectious diseases affecting the oral cavity, including periodontitis and candidiasis. In addition, several potential links with systemic inflammatory conditions, such as cardiovascular disease, are explored. The findings elucidate some of the defense mechanisms utilized by host tissues, including the role of IL-17 in providing immunity to oral candidiasis, the antimicrobial defense of mucosal epithelial cells, and the pro-resolution effects of the natural inflammatory regulators, proresolvins and lipoxins. They also describe the role of immune cells in mediating pathologic bone resorption in periodontal disease. These insights highlight the potential for therapeutic benefit of immunomodulatory interventions that bolster or modulate host defense mechanisms in both oral and systemic disease. Among the promising new therapeutic approaches discussed here are epithelial cell gene therapy, passive immunization against immune cell targets, and the use of proresolvin agents.

Indexed as

Communicable DiseasesHumansInterleukin-17Mouth DiseasesInterleukin-17bacterial invasioncytokinesfungal immunitylipoxinsoropharyngeal candidiasisperiodontal bone resorption

Identifiers

PMID24736702
PMCPMC6636230
OpenAlexW2171215089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.